Joachim Müller-Quernheim

Title: Joachim Müller-Quernheim: Innovator in Therapeutic Solutions for Lung Diseases

Introduction

Joachim Müller-Quernheim is a notable inventor based in Kirchzarten, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of interstitial lung diseases. His innovative work has led to the development of a patent that addresses critical health issues.

Latest Patents

Müller-Quernheim holds a patent titled "Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease." This invention involves an isolated soluble CCR6 receptor polypeptide that can bind to CCL18 and/or CCL20. The patent outlines methods for quantifying the concentration of this polypeptide in liquid samples from subjects. Additionally, it describes methods for detecting and prognosticating interstitial lung diseases or cancers by determining the levels of the soluble CCR6 receptor polypeptide. The invention also includes pharmaceutical compositions that inhibit the activity and/or expression of CCL18 or CCL20 for treating these diseases.

Career Highlights

Throughout his career, Müller-Quernheim has worked with prominent institutions, including Universitätsklinikum Freiburg. His research has focused on innovative therapeutic options that can significantly improve patient outcomes in lung disease treatment.

Collaborations

Müller-Quernheim has collaborated with esteemed colleagues such as Gernot Zissel and Antje Prasse. These partnerships have contributed to the advancement of research in the field of lung diseases.

Conclusion

Joachim Müller-Quernheim's work exemplifies the impact of innovation in medical research, particularly in developing therapeutic solutions for interstitial lung diseases. His contributions continue to influence the field and offer hope for improved treatments.